223 related articles for article (PubMed ID: 28472307)
21. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
22. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
23. Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.
Al Mazari A; Zomaya AY; Charleston M; Salem H; Maher A; Garsia RJ
Curr HIV Res; 2007 Jul; 5(4):430-9. PubMed ID: 17627506
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
[TBL] [Abstract][Full Text] [Related]
25. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.
Soulie C; Descamps D; Grudé M; Schneider V; Trabaud MA; Morand-Joubert L; Delaugerre C; Montes B; Barin F; Ferre V; Raymond S; Jeulin H; Alloui C; Yerly S; Pallier C; Reigadas S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 Feb; 70(2):566-72. PubMed ID: 25344810
[TBL] [Abstract][Full Text] [Related]
27. High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
de Truchis P; Lê MP; Daou M; Madougou B; Nouhou Y; Moussa Saley S; Sani A; Adehossi E; Rouveix E; Saidou M; Peytavin G; Delaugerre C
J Antimicrob Chemother; 2016 Nov; 71(11):3222-3227. PubMed ID: 27439522
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
29. Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
Mukerji SS; Misra V; Lorenz D; Cervantes-Arslanian AM; Lyons J; Chalkias S; Wurcel A; Burke D; Venna N; Morgello S; Koralnik IJ; Gabuzda D
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):246-255. PubMed ID: 28328546
[TBL] [Abstract][Full Text] [Related]
30. HIV encephalitis in a patient on antiretroviral therapy: a case report.
Hlebowicz M; Parczewski M; Jakubowski P
Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
[TBL] [Abstract][Full Text] [Related]
31. Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana.
Kelentse N; Moyo S; Mogwele M; Lechiile K; Moraka NO; Maruapula D; Seatla KK; Esele L; Molebatsi K; Leeme TB; Lawrence DS; Musonda R; Kasvosve I; Harrison TS; Jarvis JN; Gaseitsiwe S
Medicine (Baltimore); 2020 Oct; 99(41):e22606. PubMed ID: 33031315
[TBL] [Abstract][Full Text] [Related]
32. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
[TBL] [Abstract][Full Text] [Related]
33. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
[TBL] [Abstract][Full Text] [Related]
34. Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.
Bila DC; Boullosa LT; Vubil AS; Mabunda NJ; Abreu CM; Ismael N; Jani IV; Tanuri A
PLoS One; 2015; 10(7):e0130580. PubMed ID: 26151752
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment.
Sewell J; Daskalopoulou M; Nakagawa F; Lampe FC; Edwards S; Perry N; Wilkins E; O'Connell R; Jones M; Collins S; Speakman A; Phillips AN; Rodger AJ;
HIV Med; 2017 Aug; 18(7):463-473. PubMed ID: 28004523
[TBL] [Abstract][Full Text] [Related]
36. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P;
HIV Med; 2019 Mar; 20(3):202-213. PubMed ID: 30688008
[TBL] [Abstract][Full Text] [Related]
37. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
[TBL] [Abstract][Full Text] [Related]
39. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
40. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
